TRANSCODE THERAPEUTICS, INC. (RNAZ)

SEC filing

TRANSCODE THERAPEUTICS, INC.

RNAZ · CIK 1829635

4 · Sep 11, 2026 · Director, Chief Financial Officer Fitzgerald Thomas A was granted 185K Stock Option (right to buy)

Director, Chief Financial Officer Fitzgerald Thomas A was granted 185K Stock Option (right to buy)

OWNERSHIP DOCUMENT

xslF345X06/tm2625227-1_4seq1.xmlSEC.gov

Graphics and non-inline formats (not embedded below).